Editor-in-Chief, Medtech Insight, HBW Insight
Ryan Nelson has been covering the medical device and consumer health, wellness and beauty sectors since 2004, first as a reporter for The Gray Sheet, where he covered beats including Capitol Hill, international and emerging technology, and then as managing editor of The Rose Sheet. In his current role, he oversees and heads up strategy for Medtech Insight and HBW Insight. He also manages and contributes regularly to HBW Insight’s Beauty channel with a focus on regulatory, policy and legal issues and has moderated related panels at industry events. Ryan has a growing role in developing podcasts, new features, “deep dive” article series, and infographics across teams and publications. Off the job, he enjoys spending time with his wife Katie, son Finn and daughter Maggie in Alexandria, VA.
Latest From Ryan Nelson
US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs including MDUFA. Policy riders stripped from the legislation, including for FDA oversight of lab-developed tests, could still find their way into a final FY 2023 spending omnibus.
How do reasonable consumers interpret the role of collagen in L’Oreal facial skin-care products in the context of labeled benefit claims? The question is central to class action litigation being waged in New York’s Southern District.
Phoenix, AZ-based Skinbetter Science “has become one of the fastest growing medical-dispensed skincare brands in the United States,” recording nearly $95m in sales for the 12-month period ended 31 August 2022, and shows “great international potential,” according to L’Oreal leadership.
Cosmetics Industry Still Committed To Reg Modernization, But FDA User-Fee Reauthorization May Not Be Vehicle
A “clean” FDA user-fee reauthorization bill – minus cosmetics modernization provisions – could be the likeliest way forward with user-fee program funding set to elapse at the end of September, a PCPC rep suggested in an email to HBW Insight.
The Honest Company alum brings to the Independent Beauty Association an extensive R&D background and the conviction that constraints on businesses today can and should foster innovation. That said, unduly burdensome legislation threatens to have a stifling effect on cosmetics innovation, the group’s new president and CEO tells HBW Insight in Part 2 of this interview.